| 진행된 위장관암에서 저용량의 경구용 Leucovorin 과 5-Fluorouracil 의 항암 효과 |
| 문한림, 김훈교, 이경식, 정진우, 이창돈, 김부성, 김동집, 최규호, 최경업 |
|
| The Efficacy of 5-Fluorouracil and Low Dose Oral Leucovorin in Advanced GI Malignancies |
| Han Lim Moon, Hoon Kyo Kim, Kyung Shik Lee, Jin Woo Jung, Chang Don Lee, Boo Sung Kim, Dong Jip Kim, Kyu Ho Choi, Keung Eup Choi |
|
|
|
|
|
|
|
| ABSTRACT |
|
Eighteen patients with GI malignancies (9 gastric, 3 colorectal, 3 pancreatic and 3 hepatobiliary cancer) were treated with oral leucovorin 15 mg administered every 6 hrs and IV 5-fluorouracil (5-FU) 500 mg/m started 1 hr after oral leucovorin for 5 consecutive days. The cycle was repeated every 3 weeks. When grade III or IV toxicities appeared, dose of 5-FU was reduced to 80% of initial one. Eight of 18 patients had previous experience of 5-FU containing chemotherapy. The results of study showed no objective responder of 16 evaluable patients. Eleven of 16 (69%) had stable disease and 5 (31%) Progressed initially. The overall survival of the study group was 9-65+ weeks (median: 36 wks). Survival of patients with stable disease and those with initial progression were 9+-65+ weeks (median: 41 weeks) and 9-21 (median: 13) weeks retrospectively (p<0.05). Toxicities were mild and tolerable. The most common and dose limiting toxicity was mucositis (83.3%). We concluded low dose oral leucovorin and 5-FU was tolerable, but not effective in GI malignancies. |
|
PDF Links
Full text via DOI 
Download Citation 
